[go: up one dir, main page]

MX2012003204A - Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado. - Google Patents

Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.

Info

Publication number
MX2012003204A
MX2012003204A MX2012003204A MX2012003204A MX2012003204A MX 2012003204 A MX2012003204 A MX 2012003204A MX 2012003204 A MX2012003204 A MX 2012003204A MX 2012003204 A MX2012003204 A MX 2012003204A MX 2012003204 A MX2012003204 A MX 2012003204A
Authority
MX
Mexico
Prior art keywords
solid dosage
dosage form
oral solid
formulation
containing nanoparticles
Prior art date
Application number
MX2012003204A
Other languages
English (en)
Inventor
Deepak Bahl
Kieran James Crowley
Danny Yu
Original Assignee
Rp Scherer Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rp Scherer Technologies Llc filed Critical Rp Scherer Technologies Llc
Publication of MX2012003204A publication Critical patent/MX2012003204A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una forma de dosificación sólida oral que contiene nanopartículas que se hacen por: (a) la reducción del tamaño de partícula de al menos un ingrediente farmacéuticamente activo dispersado en una solución que contiene gelatina de pescado para formar una nanosuspensión; y (b) el secado por congelamiento de la nanosuspensión de la etapa (a) para formar la forma de dosificación sólida oral.
MX2012003204A 2009-09-16 2010-09-13 Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado. MX2012003204A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/560,813 US9775819B2 (en) 2009-09-16 2009-09-16 Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
PCT/US2010/048588 WO2011034809A1 (en) 2009-09-16 2010-09-13 Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin

Publications (1)

Publication Number Publication Date
MX2012003204A true MX2012003204A (es) 2012-05-29

Family

ID=43730820

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012003204A MX2012003204A (es) 2009-09-16 2010-09-13 Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.
MX2014011872A MX349106B (es) 2009-09-16 2010-09-13 Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014011872A MX349106B (es) 2009-09-16 2010-09-13 Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.

Country Status (14)

Country Link
US (1) US9775819B2 (es)
EP (1) EP2477608B1 (es)
JP (1) JP5707405B2 (es)
KR (1) KR101714688B1 (es)
CN (1) CN102686218B (es)
AR (1) AR080662A1 (es)
AU (1) AU2010295781B2 (es)
BR (1) BR112012005969A2 (es)
CA (1) CA2774210C (es)
DK (1) DK2477608T3 (es)
ES (1) ES2527225T3 (es)
IL (1) IL218598A (es)
MX (2) MX2012003204A (es)
WO (1) WO2011034809A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP2481409B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
EP3326630A3 (en) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
CN102406941B (zh) * 2011-07-29 2015-03-11 沈阳药科大学 含有改性明胶肽的纳米化难溶性活性组分及其制备方法
EP3791866B1 (en) * 2012-05-02 2025-04-23 NewMarket Pharmaceuticals LLC Pharmaceutical compositions for direct systemic introduction
DE102012221900A1 (de) 2012-11-29 2014-06-05 2LUTION GmbH Feste Lösungen von Coffein
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
EP3403725A1 (de) * 2017-05-15 2018-11-21 Eppendorf AG Pipettierhilfssystem
KR102104257B1 (ko) * 2018-05-18 2020-04-24 강원대학교산학협력단 열용융압출법을 이용하여 제조된 망간 나노콜로이드 분산체 및 이의 용도
KR102105872B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 구리 나노콜로이드 분산체 및 이의 용도
KR102105827B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 셀레늄 나노콜로이드 분산체 및 이의 용도
KR102105829B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 산화아연 나노콜로이드 분산체 및 이의 용도
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
EP3804702A1 (de) 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung einer pharmazeutischen formulierung mit wirkstoff, polymer und tensid
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4243796A4 (en) 2020-11-16 2025-01-22 Orcosa Inc. IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
WO2022216769A1 (en) * 2021-04-07 2022-10-13 Fontana Biosciences, Inc. Rapidly disintegrating allyl isothiocyanate tablet
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107502T1 (de) 1988-10-05 1994-07-15 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2087565T3 (es) 1991-12-05 1996-07-16 Alfatec Pharma Gmbh Nanosol aplicable farmaceuticamente y procedimiento para su preparacion.
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US6066337A (en) 1994-01-27 2000-05-23 The Board Of Regents Of The University Of Oklahoma And Janssen Pharmaceutica, Inc. Method for producing a rapidly dissolving dosage form
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
CA2369263A1 (en) 1999-04-09 2000-10-19 Jessie Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US7105176B2 (en) 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
FR2825293B1 (fr) 2001-06-05 2004-05-07 Coletica Particules solides insolubles dans l'eau traitees, preparation et utilisation
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
JP4878839B2 (ja) 2002-09-11 2012-02-15 エラン ファーマ インターナショナル，リミティド ゲル安定化ナノパーティクル活性物質組成物
ES2365012T3 (es) 2002-11-12 2011-09-20 Elan Pharma International Limited Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
DE10253111A1 (de) * 2002-11-13 2004-05-27 Basf Ag Pulverförmige Phytosterol-Formulierungen
AU2005269800B8 (en) 2004-07-19 2011-12-01 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US20090297596A1 (en) 2005-05-23 2009-12-03 Elan Pharma International Limited Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor
DE102005030952A1 (de) 2005-06-30 2007-01-18 Basf Ag Verfahren zur Herstellung einer wässrigen Suspension und einer pulverförmigen Zubereitung eines oder mehrerer Carotinoide
DE102005031468A1 (de) 2005-07-04 2007-01-18 Basf Ag Wässrige Suspensionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver
US9707185B2 (en) 2007-05-07 2017-07-18 Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College Water-soluble nanoparticles containing water-insoluble compounds
GB0714223D0 (en) 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
JP2010534563A (ja) 2007-07-24 2010-11-11 ネクスバイオ，インク． マイクロ粒子の作製のための技術
US20100055246A1 (en) 2008-08-28 2010-03-04 Dong June Ahn Nutrition delivery capsules for functional foods

Also Published As

Publication number Publication date
US9775819B2 (en) 2017-10-03
HK1175984A1 (en) 2013-07-19
CN102686218B (zh) 2017-12-19
IL218598A (en) 2015-09-24
JP5707405B2 (ja) 2015-04-30
EP2477608B1 (en) 2014-10-29
DK2477608T3 (en) 2015-01-19
US20110064812A1 (en) 2011-03-17
CN102686218A (zh) 2012-09-19
JP2013505243A (ja) 2013-02-14
CA2774210C (en) 2017-08-29
AU2010295781A1 (en) 2012-04-19
EP2477608A1 (en) 2012-07-25
KR101714688B1 (ko) 2017-03-09
EP2477608A4 (en) 2013-03-06
AU2010295781B2 (en) 2015-07-09
WO2011034809A1 (en) 2011-03-24
AR080662A1 (es) 2012-05-02
BR112012005969A2 (pt) 2017-06-06
IL218598A0 (en) 2012-05-31
CA2774210A1 (en) 2011-03-24
KR20120089815A (ko) 2012-08-13
ES2527225T3 (es) 2015-01-21
MX349106B (es) 2017-07-12

Similar Documents

Publication Publication Date Title
MX2012003204A (es) Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
CO2017012670A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
MX2012005677A (es) Formulaciones parentales de derivados de gemcitabina.
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
MX2016002866A (es) Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofilica.
TN2015000135A1 (en) Modified release formulations for oprozomib
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
CO6640318A2 (es) Formas de dosificación oral de bendamustina
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
MX2015011624A (es) Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
DOP2013000115A (es) Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma
TR200906506A2 (tr) Telmisartan içeren katı dozaj formları.
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2015006011A (es) Pastilla medicinal a base de ibuprofeno sodico dihidratado.
BR112012029565A2 (pt) composição farmacêutica de liberação controlada de losartana.
ECSP13012766A (es) Comprimido farmaceutico de liberación controlada para administración oral
CL2012000499A1 (es) Forma de dosificación farmacéutica sólida oral de liberación extendida que comprende una formulación matricial de liberación extendida que comprende 5 a 500 mg de clorhidrato de oxicodona y al menos 80 % (p/p) de oxido de polietileno (pm 1.000.000); y su uso para tratar el dolor (div. sol. n° 200702485).
AR082097A1 (es) Encapsulacion de ingredientes en una matriz de lactosa para formar encapsulados activos
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos
TN2010000445A1 (en) Oral and injectable formulations of tetracycline compounds

Legal Events

Date Code Title Description
FG Grant or registration